FSD Pharma Inc. HUGE FSDDF said Monday it has obtained approval for its Class B subordinate shares to list on the Nasdaq Capital Market.
The company hasn’t provided a specific date for when the stock will begin trading on the Nasdaq.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
FSD Pharma is a specialty biotech pharmaceutical research and development company oriented toward creating a variety of synthetic compounds addressing the human endocannabinoid system to help treat various central nervous system illnesses and autoimmune disorders.
During the second quarter of 2019, FSD Pharma purchased Prismic Pharmaceuticals.
FSD Pharma shares were trading 18.1% higher at $5.35 at the time of publication Monday.
Related Links:
Cannabis Earnings Roundup: 4Front, WeedMD, FSD Pharma, 1933 Industries, True Leaf
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.